Cancer Research AACR Legacy Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Rhijn, B. W. G.
Right arrow Articles by Zwarthoff, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Rhijn, B. W. G.
Right arrow Articles by Zwarthoff, E. C.
[Cancer Research 61, 1265-1268, February 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

The Fibroblast Growth Factor Receptor 3 (FGFR3) Mutation Is a Strong Indicator of Superficial Bladder Cancer with Low Recurrence Rate1

Bas W. G. van Rhijn, Irene Lurkin, François Radvanyi, Wim J. Kirkels, Theodorus H. van der Kwast and Ellen C. Zwarthoff2

Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, the Netherlands [B. W. G. v. R., I. L., T. H. v. d. K., E. C. Z.]; Department of Urology, Erasmus University and University Hospital, 3000 CA Rotterdam, the Netherlands [B. W. G. v. R., W. J. K.]; and Laboratoire de Morphogenèse Cellulaire et Progession Tumorale, UMR 144, Centre National de la Recherche Scientifique, Institut Curie, 75248 Paris Cedex 05, France [F. R.]

We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer. A FGFR3 mutation was found in 34 of 53 pTaG1–2 bladder cancers, whereas none of the 19 higher-staged tumors had a mutation (P < 0.0001). In 57 patients with superficial disease followed prospectively by cystoscopy for 12 months, 14 of 23 patients in the wild-type FGFR3 group developed recurrent bladder cancer compared with only 7 of 34 patients in the mutant group (P = 0.004). The recurrence rate per year was 0.24 for the FGFR3 mutant tumors and 1.12 for tumors with a wild-type FGFR3 gene. In addition, FGFR3 mutation status was the strongest predictor of recurrence when compared with stage and grade (P = 0.008). This is the first mutation in bladder cancer that selectively identifies patients with favorable disease characteristics. Our results suggest that the frequency of cystoscopic examinations can be reduced considerably in patients with FGFR3-positive tumors.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Kalinsky, L. M. Jacks, A. Heguy, S. Patil, M. Drobnjak, U. K. Bhanot, C. V. Hedvat, T. A. Traina, D. Solit, W. Gerald, et al.
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Clin. Cancer Res., August 15, 2009; 15(16): 5049 - 5059.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. J. Wild, T. Fuchs, R. Stoehr, D. Zimmermann, S. Frigerio, B. Padberg, I. Steiner, E. C. Zwarthoff, M. Burger, S. Denzinger, et al.
Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1798 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Cancer Res., June 1, 2009; 69(11): 4613 - 4620.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. Meyer, C. W. McAndrew, and D. J. Donoghue
Nordihydroguaiaretic Acid Inhibits an Activated Fibroblast Growth Factor Receptor 3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells
Cancer Res., September 15, 2008; 68(18): 7362 - 7370.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Martinez-Torrecuadrada, L. H. Cheung, P. Lopez-Serra, R. Barderas, M. Canamero, S. Ferreiro, M. G. Rosenblum, and J. I. Casal
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Mol. Cancer Ther., April 1, 2008; 7(4): 862 - 873.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. J. Marsit, E. A. Houseman, A. R. Schned, M. R. Karagas, and K. T. Kelsey
Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer
Carcinogenesis, August 1, 2007; 28(8): 1745 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. P. Mitra, R. H. Datar, and R. J. Cote
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification
J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Duchesne, B. Tissot, T. R. Rudd, A. Dell, and D. G. Fernig
N-Glycosylation of Fibroblast Growth Factor Receptor 1 Regulates Ligand and Heparan Sulfate Co-receptor Binding
J. Biol. Chem., September 15, 2006; 281(37): 27178 - 27189.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, A. Amoros, A. Tardon, A. Carrato, C. Serra, N. Malats, and F. X. Real
Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas
J. Clin. Oncol., August 1, 2006; 24(22): 3664 - 3671.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, et al.
TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study.
Cancer Res., July 1, 2006; 66(13): 6871 - 6876.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. Bernard-Pierrot, A. Brams, C. Dunois-Larde, A. Caillault, S. G. Diez de Medina, D. Cappellen, G. Graff, J. P. Thiery, D. Chopin, D. Ricol, et al.
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Carcinogenesis, April 1, 2006; 27(4): 740 - 747.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. A. Knowles
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Carcinogenesis, March 1, 2006; 27(3): 361 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Tomlinson, C. G. L'Hote, W. Kennedy, E. Pitt, and M. A. Knowles
Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor-Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines
Cancer Res., November 15, 2005; 65(22): 10441 - 10449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft
Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors
Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M.M. van Oers, I. Lurkin, A. J.A. van Exsel, Y. Nijsen, B. W.G. van Rhijn, M. N.M. van der Aa, and E. C. Zwarthoff
A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine
Clin. Cancer Res., November 1, 2005; 11(21): 7743 - 7748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann
Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder
Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Dyrskjot, K. Zieger, M. Kruhoffer, T. Thykjaer, J. L. Jensen, H. Primdahl, N. Aziz, N. Marcussen, K. Moller, and T. F. Orntoft
A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome
Clin. Cancer Res., June 1, 2005; 11(11): 4029 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. J. Gomez-Roman, P. Saenz, J. Cuevas Gonzalez, K. Escuredo, S. Santa Cruz, C. Junquera, L. Simon, A. Martinez, J. L. Gutierrez Banos, M. Lopez-Brea, et al.
Fibroblast Growth Factor Receptor 3 Is Overexpressed in Urinary Tract Carcinomas and Modulates the Neoplastic Cell Growth
Clin. Cancer Res., January 15, 2005; 11(2): 459 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. J. Schultz, L. A. Kiemeney, H. F.M. Karthaus, J. A. Witjes, J. L. Willems, D. W. Swinkels, J. M.T. K. Gunnewiek, and J. B. de Kok
Survivin mRNA Copy Number in Bladder Washings Predicts Tumor Recurrence in Patients with Superficial Urothelial Cell Carcinomas
Clin. Chem., August 1, 2004; 50(8): 1425 - 1428.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Dyrskjot, M. Kruhoffer, T. Thykjaer, N. Marcussen, J. L. Jensen, K. Moller, and T. F. Orntoft
Gene Expression in the Urinary Bladder: A Common Carcinoma in Situ Gene Expression Signature Exists Disregarding Histopathological Classification
Cancer Res., June 1, 2004; 64(11): 4040 - 4048.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. W. G. van Rhijn, T. H. van der Kwast, A. N. Vis, W. J. Kirkels, E. R. Boeve, A. C. Jobsis, and E. C. Zwarthoff
FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma
Cancer Res., March 15, 2004; 64(6): 1911 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. A. Bakkar, H. Wallerand, F. Radvanyi, J.-B. Lahaye, S. Pissard, L. Lecerf, J. C. Kouyoumdjian, C. C. Abbou, J.-C. Pairon, M.-C. Jaurand, et al.
FGFR3 and TP53 Gene Mutations Define Two Distinct Pathways in Urothelial Cell Carcinoma of the Bladder
Cancer Res., December 1, 2003; 63(23): 8108 - 8112.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. W.G. van Rhijn, A. N. Vis, T. H. van der Kwast, W. J. Kirkels, F. Radvanyi, E. C.M. Ooms, D. K. Chopin, E. R. Boeve, A. C. Jobsis, and E. C. Zwarthoff
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
J. Clin. Oncol., May 15, 2003; 21(10): 1912 - 1921.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. W. G. van Rhijn, I. Lurkin, D. K. Chopin, W. J. Kirkels, J.-P. Thiery, T. H. van der Kwast, F. Radvanyi, and E. C. Zwarthoff
Combined Microsatellite and FGFR3 Mutation Analysis Enables a Highly Sensitive Detection of Urothelial Cell Carcinoma in Voided Urine
Clin. Cancer Res., January 1, 2003; 9(1): 257 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tada, M. Wada, K.-i. Taguchi, Y. Mochida, N. Kinugawa, M. Tsuneyoshi, S. Naito, and M. Kuwano
The Association of Death-associated Protein Kinase Hypermethylation with Early Recurrence in Superficial Bladder Cancers
Cancer Res., July 15, 2002; 62(14): 4048 - 4053.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.